Journal
ONCOTARGET
Volume 6, Issue 6, Pages 3811-3824Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2924
Keywords
EPI-001; Bisphenol A Diglycidyl Ether; Androgen Receptor; Prostate Cancer; Peroxisome Proliferator-Activated Receptor-gamma
Categories
Funding
- National Institutes of Health [R01 CA174777]
- Department of Defense [W81WXH-12-1-0288, W81XWH-13-2-0093]
- American Cancer Society Research Scholar Grant [RSG-12-031-01]
Ask authors/readers for more resources
The androgen receptor (AR) is a driver of prostate cancer (PCa) cell growth and disease progression. Therapies for advanced PCa exploit AR dependence by blocking the production or action of androgens, but these interventions inevitably fail via multiple mechanisms including mutation or deletion of the AR ligand binding domain (LBD). Thus, the development of new inhibitors which act through non-LBD interfaces is an unmet clinical need. EPI-001 is a bisphenol A-derived compound shown to bind covalently and inhibit the AR NH2-terminal domain (NTD). Here, we demonstrate that EPI-001 has general thiol alkylating activity, resulting in multilevel inhibitory effects on AR in PCa cell lines and tissues. At least one secondary mechanism of action associated with AR inhibition was found to be selective modulation of peroxisome proliferator activated receptor-gamma (PPAR gamma). These multi-level effects of EPI-001 resulted in inhibition of transcriptional activation units (TAUs) 1 and 5 of the AR NTD, and reduced AR expression. EPI-001 inhibited growth of AR-positive and AR-negative PCa cell lines, with the highest sensitivity observed in LNCaP cells. Overall, this study provides new mechanistic insights to the chemical biology of EPI-001, and raises key issues regarding the use of covalent inhibitors of the intrinsically unstructured AR NTD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available